 Yeah, absolutely. So in 2023, Amgen released the results of a clinical trial that tested Imdeltra in patients with small cell lung cancer. Imdeltra is an antibody, and it has two arms. One of the arms is able to grab onto the small cell lung cancer cell, and the other arm grabs onto one of the patient's white blood cells, and it pulls the white blood cells into the cancer, and it unleashes the power...